Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

"Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Eli Lilly has spent recent years reintroducing itself to the public via a series of corporate campaigns, and its latest push goes a step further.

Eli Lilly is no longer just a pharmaceutical giant—it’s becoming a platform company that’s reshaping the very structure of global healthcare.

Eli Lilly is regulated by both the Federal Drug Administration and the Michigan Board of Pharmacy, neither of which have authority over pricing.

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity ...

If Eli Lilly’s latest ad is any indication, the drugmaker wants to differentiate itself from other pharma giants. How it intends to do so is by showcasing the company’s values and recruiting top ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible ...

Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.